Phio Pharmaceuticals Financial Results
Phio Pharmaceuticals reported Q3 2026 financial results, highlighting a cash position of $10.6 million. The company achieved key milestones for its PH-762 program, including the completion of commercial-scale cGMP manufacturing and the submission of Phase 1b clinical data to the FDA in preparation for a Phase 2b study initiation expected in Q1 2027.
- Term
- Q3 2026
“We have successfully executed on critical development objectives to advance the PH-762 program toward Phase 2b study initiation. Commercial-scale drug substance manufacturing was completed and shipped to our drug product manufacturer in preparation for making clinical trial supply material. We have submitted detailed information to FDA providing final analysis of our Phase 1b clinical trial and the fundamentals of our intended upcoming Phase 2b study.”
Robert J. Bitterman, President and Chief Executive Officer